Compass Pathways psilocybin refers to COMP360, a synthetic psilocybin formulation the company is developing with psychological support for treatment-resistant depression. Its Phase 3 program was underway, and COMP360 was not FDA-approved for any psychiatric indication in the latest safety context described by Cleveland Clinic.
What is Compass Pathways developing?
Compass describes COMP360 as a proprietary formulation of synthetic psilocybin given alongside psychological support. This is not a fruiting-body or mycelium mushroom product: it is a synthetic formulation used in a structured clinical-development program.
The evidence grade is clinical-stage. That means the program includes controlled human research, while regulatory approval and availability remain separate questions.
What happened in the COMP360 psilocybin trial?
A 2024 announcement from Journey Clinical describes Compass’s earlier Phase 2b study: participants with treatment-resistant depression received one 25 mg dose of COMP360 with psychological support, and the announcement reported an improvement in depressive-symptom severity after three weeks.
That study format matters. A trial result describes a specific group, dose, setting and support model; it is not the same as taking mushrooms on your own. For a clear look at why the comparison arm shapes what a trial can tell you, see mushroom trial comparator groups.
What does Compass Pathways Phase 3 mean?
Phase 3 is the later-stage part of clinical development. Compass said its Phase 3 COMP360 program for treatment-resistant depression was randomized, controlled and double-blind. The same announcement also said the company had Phase 2 studies in progress for post-traumatic stress disorder and anorexia nervosa.
For readers tracking Compass Pathways Phase 3 results, the practical distinction is simple: a Phase 3 program being underway is not the same thing as a completed result or an FDA approval.
Is Compass Pathways psilocybin FDA approved?
No. Cleveland Clinic’s safety report states that psilocybin remained investigational and was not FDA-approved for any psychiatric indication. Journey Clinical’s 2024 announcement says COMP360 had received FDA Breakthrough Therapy designation for treatment-resistant depression; that designation supports development but is not marketing approval.
What is in the Compass pipeline?
| Program | What it is | Development described |
|---|---|---|
| COMP360 | Synthetic psilocybin with psychological support | Phase 3 program for treatment-resistant depression |
| COMP360 | Synthetic psilocybin with psychological support | Phase 2 studies for PTSD and anorexia nervosa |
Compass and Journey Clinical also announced a research collaboration focused on possible delivery, provider training and reimbursement pathways if COMP360 receives approval.
Why can the name COMPASS be confusing?
A 2019 PubMed-indexed study uses COMPASS as the name of a synthetic-biology method for assembling gene pathways in yeast; it is separate from Compass Pathways and COMP360 psilocybin research.
Why is Compass Pathways stock down today?
Same-day stock moves can reflect many things, including clinical-development updates, financing expectations and broader market trading. For current company news, earnings releases and investor materials, use Compass Pathways’ investor-relations channels named in the Journey Clinical announcement rather than treating an older trial update as an explanation for today’s price movement.
What safety question matters most?
Psilocybin research is not a substitute for self-directed use. Cleveland Clinic reported a case involving a person who took Psilocybe cubensis while taking tranylcypromine, an MAOI, and dextroamphetamine-amphetamine; the report describes severe hypertension and chest pain. If you take prescription medicines, speak with the clinician managing them before making any change or considering a psychedelic substance.
COMP360 is synthetic, whereas whole mushrooms can contain psilocybin, psilocin and other alkaloids. Psilocybin brain effects explains the broader research and safety context.
Before you follow Compass Pathways news
- Separate an investigational program from an approved treatment.
- Check whether a headline concerns Phase 3 enrollment, results, regulatory news or the company’s stock.
- Keep the trial setting in view: the COMP360 model described here includes psychological support.
- Ask the clinician managing your medicines about interaction questions rather than changing a medication yourself.
By MushroomHealthBenefits.com Research & Editorial Team